Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 14

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 14
---
3 vs. S&P Biotechnology Select Industry Index (XBI) - 17% and Vaccine Peer Median +9% 4 2

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 18 | Investing in Growth and Opportunistic Capital Return are n ot Mutually Exclusive Investing in Attractive Opportunities Opportunistically Returning Capital to Stockholders & Drive Growth in HEPLISAV - B Advance Differentiated Vaccine Pipeline Identify Strategic Opportunities to Accelerate Growth Achieve at least 60% total U.S. market share by 2030 Shingles, Plague, Pandemic Flu and Lyme Disease programs in development Leverage our unique capabilities and expertise Authorized $200M share repurchase program in connection with strategic business updates in Nov 2024 1 2 3 4 Dynavax’s Strategy is Delivering Value for Stockholders The best path forward is to leverage our proven ability to develop and commercialize market - leading vaccines while opportunistically returning capital to stockholders

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx This is the Optimal Board to Drive our Value Creation Potential 19 |

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx P Highly Successful Commercialization of a Market - Leading Vaccine: HEPLISAV - B is now the market share leader in the hepatitis B US adult vaccine market and generated $268M in net product revenue in 2024 P Development of an Innovative, Differentiated Pipeline: This includes our Phase 2 shingles vaccine candidate that could disrupt a $4.2B market and a plague vaccine program in partnership with the US Department of Defense P Successful Business Development Strategy During Pandemic: Established a global portfolio of CpG 1018 adjuvant commercial supply agreements supporting the development of COVID - 19 vaccines, which generated